Bain Capital Life Sciences led a $215m Series D financing round in Atea Pharmaceuticals, a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. The financing round saw investments from RA Capital Management, Perceptive Advisors, Rock Springs Capital, Adage Capital Management, Redmile Group, and Omega Funds. Existing Atea investors, including Morningside Ventures, Cormorant Asset Management, Ally Bridge Group, and Sectoral Asset Management, as well as other investors. "Atea’s team has an outstanding track record in developing novel, potent DAAs, which we believe can contribute to the urgent fight against the Covid-19 pandemic and other RNA viruses. We are pleased to partner with Atea’s leadership team and an outstanding group of leading healthcare investors as Atea advances its diverse pipeline of transformative antiviral medicines," Andrew Hack, Bain Capital Life Sciences Managing Director.